广式“加速器”四招助力新药研制

Core Insights - The article discusses the establishment and significance of the National Key Laboratory for Bioactive Molecules and Drugability Optimization, which aims to enhance the biopharmaceutical industry in Guangdong Province, a key area for future competitiveness in China [3][4]. Group 1: Laboratory Overview - The laboratory, led by Professor Ye Wencai, includes over 150 researchers, with more than 40 being national-level talents, and aims to create a world-class source for innovative drug transformation [5]. - It was officially approved for construction in March 2023, addressing challenges in original innovation for major diseases and enhancing China's pharmaceutical technology strength [4][5]. Group 2: Research and Development Methodology - The laboratory employs a unique research paradigm based on "phenotype" or "phenotype + target" for drug development, leveraging China's rich resources in traditional Chinese medicine and natural drugs [6]. - This approach allows for the direct screening of active ingredients from traditional medicine and their optimization based on target confirmation, significantly improving the success rate of new drug development [6][7]. Group 3: Technological Innovations - The laboratory has established a complete technical chain from discovery to evaluation, including strategies for efficient discovery of bioactive molecules, optimization of lead compounds, and advanced manufacturing techniques [7][8]. - Key technologies developed include a new strategy for directional discovery of natural compounds, optimization techniques for drugability, and the establishment of various large animal disease models for research [7][8]. Group 4: Industry Impact and Collaboration - The laboratory's research pipeline covers multiple drug development areas, including tissue repair, anti-tumor, anti-viral, and neurological diseases, with several new drugs already approved for market [9][10]. - It has positively influenced over 30 biopharmaceutical companies, incubated four listed companies, and contributed over 20 billion yuan in new value to related enterprises in the past five years [10]. Group 5: Recommendations for Industry Development - To promote high-quality development in Guangdong's biopharmaceutical industry, it is recommended to strengthen source innovation, support long-term investments, and fill gaps in the industrial chain [11]. - The establishment of a talent mechanism that attracts interdisciplinary professionals and a results-oriented evaluation system is crucial for enhancing research and development [11].